S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

AgeX Therapeutics Stock Price, News & Analysis (NYSE:AGE)

$0.39
-0.01 (-2.50%)
(As of 11/28/2023 ET)
Compare
Today's Range
$0.39
▼
$0.41
50-Day Range
$0.37
▼
$0.78
52-Week Range
$0.33
▼
$1.00
Volume
137,440 shs
Average Volume
78,793 shs
Market Capitalization
$14.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsSocial Media

AGE stock logo

About AgeX Therapeutics Stock (NYSE:AGE)

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

AGE Stock Price History

AGE Stock News Headlines

November 17, 2023 | msn.com
What's Going On With Penny Stock AgeX Therapeutics?
November 17, 2023 | finance.yahoo.com
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
November 28, 2023 | RYSE INC. (Ad)
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
November 14, 2023 | msn.com
AgeX Therapeutics GAAP EPS of -$0.14, revenue of $0.06M
November 14, 2023 | finance.yahoo.com
AgeX Therapeutics Reports Third Quarter 2023 Financial Results
November 6, 2023 | benzinga.com
Obesity Pipeline | Clinical Trials, Key Companies – Aardvark, Adocia, Agentix AgeX Therapeutics
August 31, 2023 | msn.com
Serina Therapeutics to merge with subsidiary of AgeX
August 30, 2023 | benzinga.com
Shareholder Alert: Ademi LLP investigates whether AgeX Therapeutics, Inc. has obtained a Fair Price in its transaction with Serina
November 28, 2023 | RYSE INC. (Ad)
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
August 30, 2023 | seekingalpha.com
Serina Therapeutics and Agex Therapeutics enter merger agreement
August 30, 2023 | marketwatch.com
AgeX Therapeutics Shares Rise Premarket on Reverse Merger Deal >AGE
August 30, 2023 | finance.yahoo.com
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
August 14, 2023 | finance.yahoo.com
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
July 24, 2023 | finance.yahoo.com
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
July 21, 2023 | seekingalpha.com
AgeX issues preferred stock to Juvenescence to nix $36M debt
June 28, 2023 | finance.yahoo.com
25 States with the Highest Life Expectancy in the US
May 17, 2023 | finance.yahoo.com
NYSE American to Suspend Trading Immediately in AgeX Therapeutics, Inc. (AGE) and Commence Delisting Proceedings
May 17, 2023 | businesswire.com
CORRECTING and REPLACING NYSE American to Commence Delisting Proceedings Against AgeX Therapeutics, Inc. (AGE)
May 12, 2023 | seekingalpha.com
AgeX Therapeutics GAAP EPS of -$0.09, revenue of $0.01M
May 12, 2023 | marketwatch.com
AgeX Therapeutics Says Projected Cash Flows Raise Going Concern Doubts
May 12, 2023 | finance.yahoo.com
AgeX Therapeutics Reports First Quarter 2023 Financial Results
March 31, 2023 | finance.yahoo.com
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
March 30, 2023 | seekingalpha.com
AGE AgeX Therapeutics, Inc.
March 16, 2023 | msn.com
Tonix starts enrollment in mid-stage study of depression drug TNX-601 ER
March 16, 2023 | msn.com
AgeX Therapeutics gets $10M loan ahead of potential restructuring
February 21, 2023 | 247wallst.com
Juvenescence Now Owns 75.60% of AgeX Therapeutics
February 13, 2023 | marketwatch.com
Anti-Senescence Therapy Market Industry Analysis Database for Period from 2023-2028
See More Headlines
Receive AGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:AGE
CUSIP
N/A
CIK
1708599
Web
www.agexinc.com
Phone
(510) 671-8370
Fax
510-871-4154
Employees
5
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,460,000.00
Net Margins
-14,946.81%
Pretax Margin
-15,014.89%
Return on Equity
N/A
Return on Assets
-139.60%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.36
Quick Ratio
0.36

Sales & Book Value

Annual Sales
$73,000.00
Price / Sales
207.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.46) per share
Price / Book
-0.87

Miscellaneous

Outstanding Shares
37,951,000
Free Float
35,484,000
Market Cap
$15.18 million
Optionable
Not Optionable
Beta
1.71
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Joanne M. Hackett Ph.D. (Age 44)
    Independent Interim CEO & Chairman of the Board
    Comp: $55.74k
  • Ms. Eun-Jae Park CPA (Age 51)
    Chief Financial Officer
    Comp: $295.29k
  • Dr. Nafees Naseer Malik M.D. (Age 45)
    Chief Operating Officer
    Comp: $282.27k
  • Dr. Ivan Labat
    Chief Information Officer
  • Ms. Judith Segall (Age 70)
    Secretary

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions














AGE Stock Analysis - Frequently Asked Questions

How have AGE shares performed in 2023?

AgeX Therapeutics' stock was trading at $0.5519 at the beginning of 2023. Since then, AGE shares have decreased by 29.3% and is now trading at $0.39.
View the best growth stocks for 2023 here.

How were AgeX Therapeutics' earnings last quarter?

AgeX Therapeutics, Inc. (NYSE:AGE) issued its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.14) EPS for the quarter. The firm earned $0.07 million during the quarter.

What other stocks do shareholders of AgeX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AgeX Therapeutics investors own include Biocept (BIOC), Allena Pharmaceuticals (ALNA), Co-Diagnostics (CODX), Moleculin Biotech (MBRX), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), AIM ImmunoTech (AIM), AzurRx BioPharma (AZRX) and Digital Ally (DGLY).

Who are AgeX Therapeutics' major shareholders?

AgeX Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Sigma Planning Corp (0.48%).
View institutional ownership trends.

How do I buy shares of AgeX Therapeutics?

Shares of AGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:AGE) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -